Puntos de vista sobre la prevención de la reestenosis dentro del stent después del implante de un stent de metal desnudo con valsartán más allá del ensayo VALVACE
Salud(i)ciencia (Impresa); 15 (6), 2007
The VALVACE trial suggests that prevention of in-stent-restenosis after implantation of bare-metal stents is possible by administration of 80mg valsartan exclusively in those patients with initial acute coronary syndrome and diabetes. The hypothesis was tested whether higher dosage valsartan is able to r...